Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
Acquisition of Worldwide Rights to Proleukin® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy Positive FDA Feedback on Phase 3... | January 23, 2023
Jen Saunders Sara Pellegrino Iovance Biotherapeutics Exchange Commission Iovance Biotherapeutics Inc Drug Administration
Source: marketscreener.com